To access this material please log in or register

Register Authorize

Effect of coenzyme Q₁₀ used as a part of standard therapy on plasma levels of brain natriuretic peptide in patients with chronic heart failure

Tokareva O. G., Kharitonova E. V., Mareev V. Yu., Kalenikova E. I., Medvedev O. S.
Federal State Budgetary Educational Institution of Higher Professional Education “M. V. Lomonosov Moscow State University”, Leninskie Gory 1, GSP-1, Moscow 119991

Keywords: coenzyme Q, natriuretic peptide, CHF

DOI: 10.18087/rhfj.2014.4.2002

Background. Along with a standard therapy for CHF, additional myocardial cytoprotection is highly significant as it restricts increased production of reactive oxygen species and enhances effectiveness of energy-dependent processes. One of cardioprotectors recommended for the use in CHF is coenzyme Q10 (CoQ10). Aim. To study effects of ubidecarenone (coenzyme Q10, Kudesan®) on plasma level of brain natriuretic peptide (BNP) in patients with FC II-III CHF. Materials and methods. The study included 78 patients aged 40 to 70 years with FC I-III CHF. Participants of the study received CoQ10 (90 mg / day) or placebo as a supplement to their standard therapy for 24 weeks. Before the treatment and in 6 months, LV EF was measured, 6-min walk test was performed, and blood plasma was collected for measuring BNP and CoQ10 in all patients. Results. Long-term CoQ10 treatment prevented progression of CHF associated with impaired myocardial contractility and normal baseline BNP levels (below 100 pg / ml). In patients with increased baseline BNP levels (above 100 pg/ml) addition of the CoQ10 drug to the standard therapy significantly reduced BNP levels, increased LV EF, and enhanced exercise tolerance.
  1. Araújo AA, Sousa MM, Silva EP et al. Clinical and epidemiological profile of patients suffering from heart Failure. J Nurs. 2014;8 (3):509–513.
  2. Popolo A, Autore G, Pinto A, Marzocco S. Oxidative stress in patients with cardiovascular disease and chronic renal failure. Free Radic Res. 2013 May;47 (5):346–56.
  3. Каленикова Е. И., Городецкая Е. А., Медведев О. С. Фармако­кинетика коэнзима Q10. Бюллетень экспериментальной биологии и медицины. 2008;146 (9):288–291.
  4. Molyneux SL, Florkowski CM, George PM et al. Coenzyme Q10: an independent predictor of mortality in chronic heart failure.J Am Coll Cardiol. 2008;52 (18):1435–1441.
  5. Березин А. Е. Биологические маркеры при хронической сердечной недостаточности: ожидания, реальность, перспективы. Серцева недостатність. 2013;1:5–15.
  6. Remme WJ, Swedberg K. Guidelines for the diagnosis and treatment of chronic heart failure. Task force for the diagnosis and treatment of chronic heart failure, European Society of Cardiology. Eur Heart J. 2001;22 (17):1527–1560.
  7. Januzzi JL Jr. Natriuretic peptide testing: a window into the diagnosis and prognosis of heart failure. Cleve Clin J Med. 2006;73 (2):149–152, 155–157.
  8. Tsutamoto T, Wada A, Maeda K et al. Plasma brain natriuretic peptide level as a biochemical marker of morbidity and mortality inpatients with asymptomatic or minimally symptomatic left ventricular dysfunction. Comparison plasma angiotensin II and endothelin-1. Eur Heart J. 1999;20 (24):1799–1807.
  9. Lass A, Sohal RS. Comparisons of coenzyme Q bound to mitochondrial membrane proteins among different mammalian species. Free Radic Biol Med. 1999 Jul;27 (1-2):220–6.
  10. Kalenikova EI, Gorodetskaya EA, Kolokolchikova EG et al. Chronic administration of coenzyme Q10 limits postinfarct myocardial remodeling in rats. Biochemistry (Mosc). 2007 Mar;72 (3):332–8.
  11. Dickstein K, Cohen-Solal A, Filippatos G et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur Heart J. 2008;29 (19):2388–2442.
  12. Karakiliç E, Kepez A, Abali G et al. The relationship between B-type natriuretic peptide levels and echocardiographic parameters in patients with heart failure admitted to the emergency department. Anadolu Kardiyol Derg. 2010 Apr;10 (2):143–9.
  13. Национальные рекомендации ВНОК и ОССН по диагностике и лечению ХСН (третий пересмотр). Журнал Сердечная Недостаточность. 2010;11 (1):3–62.
Tokareva O. G., Kharitonova E. V., Mareev V. Yu. et al. Effect of coenzyme Q₁₀ used as a part of standard therapy on plasma levels of brain natriuretic peptide in patients with chronic heart failure. Russian Heart Failure Journal. 2014;85 (4):232–237

To access this material please log in or register

Register Authorize
Ru En